Pulmatrix (PULM) Liabilities and Shareholders Equity (2014 - 2026)
Pulmatrix (PULM) posted Liabilities and Shareholders Equity of $4.5 million for Q1 2026, up 8.63% sequentially from $4.1 million in Q4 2025, and down 44.16% YoY from $8.1 million in Q1 2025.
Pulmatrix (PULM) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Pulmatrix has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $4.5 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 44.16% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 million (down 56.34% YoY) and the FY2025 annual result came in at $4.1 million, down 58.37% from the prior year.
- Liabilities and Shareholders Equity rose to $4.5 million in Q1 2026 per PULM's latest filing, from $4.1 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $54.3 million in Q1 2022 and troughed at $4.1 million in Q4 2025.
- A 5-year average of $25.0 million and a median of $30.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity declined 15.72% in 2024, then tumbled 73.51% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $41.0 million in 2022, then fell by 17.08% to $34.0 million in 2023, then slumped by 70.72% to $9.9 million in 2024, then tumbled by 58.37% to $4.1 million in 2025, then climbed by 8.63% to $4.5 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $4.5 million, $4.1 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | 3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.25 Mn |
| Mar 31, 2026 | 4.50 Mn |
| Dec 31, 2025 | 4.14 Mn |
| Sep 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 6.15 Mn |
| Mar 31, 2025 | 8.05 Mn |
| Dec 31, 2024 | 9.94 Mn |
| Sep 30, 2024 | 11.51 Mn |
| Jun 30, 2024 | 15.78 Mn |
| Mar 31, 2024 | 30.39 Mn |
| Dec 31, 2023 | 33.96 Mn |
| Sep 30, 2023 | 36.77 Mn |
| Jun 30, 2023 | 31.39 Mn |
| Mar 31, 2023 | 36.06 Mn |
| Dec 31, 2022 | 40.95 Mn |
| Sep 30, 2022 | 46.45 Mn |
| Jun 30, 2022 | 49.40 Mn |
| Mar 31, 2022 | 54.30 Mn |
| Dec 31, 2021 | 58.82 Mn |
| Sep 30, 2021 | 55.75 Mn |